Pediatric Neuromuscular Disorders

Pediatric neuromuscular disorders encompass a diverse spectrum of conditions affecting the anterior horn cell, peripheral nerve, neuromuscular junction, and muscle fiber in children. Advances in genetic testing, newborn screening, and disease-modifying therapies have fundamentally transformed the diagnostic approach and prognosis for many of these conditions. Early recognition remains critical, as the therapeutic window for emerging gene therapies and antisense oligonucleotides is narrow, and presymptomatic treatment yields markedly superior outcomes. The evaluation of the hypotonic or weak child requires systematic anatomic localization, targeted genetic and electrodiagnostic testing, and multidisciplinary management from diagnosis through the transition to adult care.

The Floppy Infant

Neonatal hypotonia — the “floppy infant” — is the principal presenting feature of most neuromuscular disorders in newborns. The initial diagnostic step is determining whether the hypotonia originates centrally (upper motor neuron or brain) or peripherally (lower motor unit). This distinction guides all subsequent evaluation and is often achievable through careful history and physical examination alone.

Differential Diagnosis of the Floppy Infant

Childhood Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is an autosomal recessive disorder caused by homozygous deletion or mutation of the SMN1 gene on chromosome 5q13. The copy number of the paralogous SMN2 gene is the primary disease modifier, as it produces small amounts of functional SMN protein. The availability of three disease-modifying therapies and the expansion of newborn screening programs have fundamentally altered the natural history and classification of SMA.

Treatment Revolution

Three disease-modifying therapies are now approved, each targeting SMN protein production through distinct mechanisms:

• Nusinersen (Spinraza): Antisense oligonucleotide administered intrathecally; modifies SMN2 splicing to increase full-length SMN protein production. Approved 2016.
• Onasemnogene abeparvovec (Zolgensma): AAV9-based gene replacement therapy delivering a functional SMN1 gene via single intravenous infusion. Approved for children <2 years (2019).
• Risdiplam (Evrysdi): Oral small molecule SMN2 splicing modifier; daily administration. Approved 2020.

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the DMD gene, resulting in absent or severely deficient dystrophin protein. With an incidence of approximately 1 in 3,500–5,000 male births, DMD is the most common severe childhood muscular dystrophy. Progressive myofiber degeneration leads to loss of ambulation by age 10–13 years and cardiorespiratory failure in early adulthood without treatment.

Clinical Presentation

• Delayed motor milestones with symptom onset typically between ages 2–5 years
• Progressive proximal weakness: difficulty running, climbing stairs, and rising from the floor
• Gowers sign: The child uses hands to “climb up” the legs when rising from the floor, reflecting hip and proximal leg weakness
• Pseudohypertrophy of the calf muscles due to fibrofatty replacement
• Waddling (Trendelenburg) gait and lumbar hyperlordosis
• Markedly elevated serum CK (typically 10,000–50,000 IU/L)

Cardiac Involvement

Cardiomyopathy is nearly universal by the second decade. Dilated cardiomyopathy with progressive left ventricular dysfunction is the primary cardiac manifestation. Current guidelines recommend cardiac MRI or echocardiography starting at diagnosis and prophylactic initiation of ACE inhibitors or angiotensin receptor blockers by age 10 (or at the first sign of dysfunction), with beta-blockers added as needed.

Management

• Corticosteroids: Prednisone or deflazacort remains the standard of care, slowing muscle degeneration and prolonging ambulation by 2–5 years. Side effects include weight gain, growth suppression, bone density loss, and behavioral changes.
• Exon-skipping therapies: Antisense oligonucleotides restore a partially functional dystrophin reading frame in patients with amenable mutations. FDA-approved agents include eteplirsen (exon 51), golodirsen (exon 53), casimersen (exon 45), and viltolarsen (exon 53). Approximately 30% of DMD patients are amenable to exon 51 skipping.
• Gene therapy: Micro-dystrophin gene transfer (delandistrogene moxeparvovec) received accelerated FDA approval in 2023 for ambulatory boys aged 4–5 years.
• Multidisciplinary care: Pulmonary function monitoring, scoliosis management, physiotherapy, and psychosocial support are essential components of long-term management.

Juvenile Myasthenia Gravis

Juvenile myasthenia gravis (JMG) accounts for 10–15% of all autoimmune MG cases and has important differences from the adult form, particularly in prepubertal children. The distinction between prepubertal and postpubertal onset has significant implications for serology, treatment approach, and prognosis.

Treatment begins with pyridostigmine for symptomatic relief. In cases with inadequate control, corticosteroids and steroid-sparing immunosuppressants (azathioprine, mycophenolate) are added. IVIG and plasma exchange are used for myasthenic crisis or perioperative management. No formal international JMG treatment guidelines exist, and management decisions are largely extrapolated from adult data.

Pediatric Guillain–Barré Syndrome

Guillain–Barré syndrome (GBS) in children shares the core pathology of immune-mediated peripheral nerve injury seen in adults but differs in several important respects. Overall prognosis is significantly better, with 90–95% of pediatric patients achieving full functional recovery.

Key Differences from Adult GBS

• AMAN prevalence: The acute motor axonal neuropathy (AMAN) subtype is more common in children, particularly in Asia and South America, often preceded by Campylobacter jejuni infection (seropositive in 70–75% of pediatric AMAN cases)
• Recovery: Full recovery in 90–95% of children versus approximately 60–80% in adults; pediatric GBS has a more favorable long-term prognosis even in cases requiring ICU admission
• Atypical presentations: Pain and irritability may be the predominant initial features in young children, preceding obvious weakness
• Prognostic factors: Poor-outcome predictors identified in adults (older age, mechanical ventilation, axonal pattern) are less predictive in children
• Late sequelae: Up to two-thirds of children may have subtle late-onset sequelae (fatigue, mild weakness, pain) that affect daily activities, despite apparent motor recovery

Treatment is with IVIG (first-line) or plasma exchange. Corticosteroids are not effective. Supportive care including respiratory monitoring, pain management, and rehabilitation is essential.

Congenital Myasthenic Syndromes

Congenital myasthenic syndromes (CMS) are genetically determined disorders of neuromuscular transmission that are distinct from autoimmune myasthenia gravis. Pathogenic variants have been identified in over 40 genes affecting presynaptic, synaptic, and postsynaptic components of the neuromuscular junction. Accurate genetic diagnosis is essential because treatment is subtype-specific, and drugs beneficial in one form may be harmful in another.

Congenital Myopathies

The congenital myopathies are a genetically heterogeneous group of early-onset, nondystrophic neuromuscular disorders defined by characteristic structural abnormalities on muscle biopsy. Serum CK is normal or only mildly elevated, distinguishing them from muscular dystrophies. Three main histopathological categories are recognized:

Nemaline Myopathy

• Characterized by rod-like inclusions (nemaline bodies) composed of alpha-actinin and Z-band filaments, visualized on Gomori trichrome staining
• Incidence approximately 1:50,000 live births; higher in Ashkenazi Jewish and Amish populations
• Clinical spectrum ranges from severe neonatal form (respiratory failure, feeding difficulty) to mild childhood form (proximal weakness, facial weakness, slow progression)
• Associated genes include NEB (most common, autosomal recessive), ACTA1, TPM2, TPM3

Centronuclear Myopathy

• Defined by abnormally centralized nuclei in muscle fibers; incidence approximately 1:41,000 births
• X-linked myotubular myopathy (MTM1): Most severe form; presents at birth with profound hypotonia, respiratory failure, and ophthalmoplegia in males
• Autosomal dominant (DNM2): Milder, later-onset form with slowly progressive weakness
• Respiratory and bulbar involvement common; nocturnal hypoventilation may require monitoring

Core Myopathies

• Central core disease: Associated with RYR1 mutations; presents with proximal weakness and hypotonia; important association with malignant hyperthermia susceptibility
• Multiminicore disease: Multiple small cores on oxidative staining; linked to SEPN1 and RYR1 mutations; axial weakness and respiratory involvement
• No specific pharmacologic treatment for congenital myopathies; management is supportive with physiotherapy, respiratory monitoring, orthopedic care, and nutritional support

Transition of Care: Pediatric to Adult Neuromuscular Clinic

Advances in disease-modifying therapies have dramatically improved survival, with over 90% of individuals with childhood-onset neuromuscular diseases now living into adulthood. The transition from pediatric to adult care is a structured, planned process that extends beyond simple transfer of medical records.

• Multidisciplinary coordination: Neuromuscular transition requires parallel handover of neurology, pulmonology, cardiology, orthopedic, and psychosocial services
• Key barriers: Limited adult specialist expertise in childhood-onset NMDs, inadequate communication between pediatric and adult providers, insurance discontinuities, and lack of designated transition coordinators (absent in 79% of surveyed clinics)
• Patient and family anxiety: Nearly 50% of families report significant anxiety about transition; long-standing relationships with pediatric teams create emotional barriers
• Timing: Transition planning should begin at age 12–14 and be individualized based on disease complexity, cognitive ability, and psychosocial readiness
• Self-advocacy skills: Gradually shifting medical responsibility from parents to the adolescent, including medication management, appointment scheduling, and understanding their diagnosis
• Respiratory transition: Patients on chronic ventilation require particular attention, as adult pulmonology practices may have limited experience with childhood-onset ventilator-dependent respiratory failure
• Psychosocial needs: Depression, anxiety, and social isolation are common in adolescents with NMDs and should be addressed proactively as part of the transition plan

References

1. Darras BT. Neuromuscular disorders in the newborn. Clin Perinatol. 2006;33(4):899–918.
2. Laugel V, et al. Assessing floppy infants: a new module. Eur J Pediatr. 2022;181(8):2919–2929.
3. Mercuri E, et al. Neonatal presentations of neuromuscular disorders. Semin Fetal Neonatal Med. 2022;27(3):101361.
4. Ching KJ, et al. Neuromuscular junction disorders and floppy infant syndrome: a comprehensive review. Children (Basel). 2020;7(2):15.
5. Mercuri E, et al. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8(1):52.
6. De Vivo DC, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842–856.
7. Strauss KA, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1390–1397.
8. Vrscaj E, et al. Newborn screening programs for spinal muscular atrophy worldwide in 2023. Neuromuscul Disord. 2024;34(6):101–109.
9. Duan D, et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.
10. Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251–267.
11. Syed YY. Eteplirsen: first global approval. Drugs. 2016;76(17):1699–1704.
12. Abreu NJ, et al. Viltolarsen: a review in Duchenne muscular dystrophy. Drugs. 2024;84(4):439–456.
13. Della Marina A, et al. Juvenile myasthenia gravis: a paediatric perspective. Arch Dis Child. 2011;96(12):1155–1160.
14. Heckmann JM, et al. Management of juvenile myasthenia gravis. Front Neurol. 2020;11:743.
15. Estublier C, et al. Long-term outcomes of paediatric Guillain–Barré syndrome. Dev Med Child Neurol. 2024;66(3):312–320.
16. Korinthenberg R, et al. Diagnosis and treatment of Guillain–Barré syndrome in childhood and adolescence: an evidence- and consensus-based guideline. Eur J Paediatr Neurol. 2020;25:5–16.
17. Engel AG, et al. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 2015;14(4):420–434.
18. Finsterer J. Congenital myasthenic syndromes: increasingly complex. Curr Opin Neurol. 2024;37(5):489–497.
19. Abicht A, et al. Review of 40 genes causing congenital myasthenic syndromes. J Hum Genet. 2025;70(2):89–101.
20. North KN, et al. Congenital myopathies: clinical phenotypes and new diagnostic tools. Neuropathol Appl Neurobiol. 2014;40(1):62–81.
21. Jungbluth H, et al. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis. 2008;3:26.
22. Jungbluth H, et al. Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction. Nat Rev Neurol. 2018;14(3):151–167.
23. Wozow KN, et al. Transitions from pediatric to adult neuromuscular care: a practical guide. Muscle Nerve. 2025;71(2):212–222.
24. Bianco F, et al. Neuromuscular disorders and transition from pediatric to adult care in a multidisciplinary perspective: a narrative review. Eur J Transl Myol. 2023;33(1):11064.